Overview

Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA

Status:
COMPLETED

Trial end date:
2025-05-22

Target enrollment:

Participant gender:

Summary

This is a phase 1, randomized, placebo-controlled, blinded study in up to 36 healthy adults, aged 18-45 years, challenged with Enterotoxigenic Escherichia coli, evaluating the safety, tolerability and anti-diarrheal activity of VENBETA6890, an orally administered, human monoclonal IgA.

Phase:

PHASE1

Details

Lead Sponsor:

Mark Klempner

Collaborators:

Bill and Melinda Gates Foundation
Pharmaron CPC, Inc.
University of Maryland